Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection.
10.1007/s11684-020-0822-5
- Author:
Yun TAN
1
;
Feng LIU
1
;
Xiaoguang XU
1
;
Yun LING
2
;
Weijin HUANG
3
;
Zhaoqin ZHU
2
;
Mingquan GUO
2
;
Yixiao LIN
2
;
Ziyu FU
1
;
Dongguo LIANG
1
;
Tengfei ZHANG
2
;
Jian FAN
2
;
Miao XU
3
;
Hongzhou LU
4
;
Saijuan CHEN
5
Author Information
1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Shanghai Public Health Clinical Center, Shanghai, 201508, China.
3. National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
4. Shanghai Public Health Clinical Center, Shanghai, 201508, China. luhongzhou@shphc.org.cn.
5. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. sjchen@stn.sh.cn.
- Publication Type:Journal Article
- Keywords:
SARS-CoV-2;
T-cell response;
neutralizing antibodies
- MeSH:
Adaptive Immunity/physiology*;
Adult;
Aged;
Antibodies, Neutralizing/blood*;
COVID-19/immunology*;
Cohort Studies;
Female;
Humans;
Immunoglobulin G/blood*;
Male;
Middle Aged;
SARS-CoV-2/immunology*;
T-Lymphocytes/physiology*;
Time Factors;
Viral Proteins/immunology*
- From:
Frontiers of Medicine
2020;14(6):746-751
- CountryChina
- Language:English
-
Abstract:
The ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered β Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients at 6-7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive for IgGs against the S- and N-proteins of SARS-CoV-2. Notably, 14 samples available at 6-7 months post-infection all showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entry of the 614D and 614G variants of SARS-CoV-2. Furthermore, in 10 blood samples from cases at 6-7 months post-infection used for memory T-cell tests, we found that interferon γ-producing CD4
